ACET Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ACET is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some bullish elements from analyst coverage and options positioning, but the technical setup is only neutral and the latest financials still show a loss-making business with no revenue in the latest quarter. Since there is no clear Intellectia buy signal and no recent news catalyst, the best call based on the current data is to hold and wait for clearer confirmation.
ACET is trading near 8.48 after a small decline from the prior close of 8.55. RSI_6 at 58.7 is neutral to mildly positive, while the MACD histogram is above zero at 0.0453 but contracting, which suggests momentum is positive but weakening. Moving averages are converging, pointing to a consolidation phase rather than a strong trend. Key levels are pivot 8.08, resistance 8.69 and 9.06, with support at 7.47 and 7.10. Overall, the chart shows a sideways-to-slightly bullish setup, but not a decisive breakout pattern.
["Jefferies initiated coverage with a Buy rating and a $19 price target, well above the current price.", "Guggenheim and H.C. Wainwright both kept Buy ratings despite lowering targets, showing continued positive analyst support.", "Options positioning is bullish with a low put-call ratio of 0.19.", "The company is described by analysts as having a catalyst-rich calendar ahead and encouraging early Phase I data."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "Hedge funds are neutral and insiders are neutral, with no notable accumulation signal.", "The stock still trades on skepticism around the pipeline and target selection relative to peers.", "Financials remain weak, with no revenue in the latest quarter and a net loss of $30.5 million.", "The MACD histogram is positive but contracting, which weakens the near-term momentum case."]
In 2025/Q4, ACET reported no revenue, unchanged year over year, while net income was negative at -$30.52 million, though slightly improved by 6.23% YoY. EPS was -4.43, worse by 12.45% YoY. Gross margin remained 0. This indicates the company is still in a pre-revenue or very early commercialization stage, with improving losses but no meaningful operating growth yet.
Analyst sentiment is still constructive overall. Jefferies initiated coverage on 2026-05-04 with a Buy and $19 target, citing encouraging early Phase I data. Earlier, H.C. Wainwright kept a Buy but cut its target to $27 from $50 due to higher operating expenses, and Guggenheim kept a Buy while cutting its target to $100 from $128 after the Q4 update. The Wall Street view is bullish on the pipeline and upcoming catalysts, but the target cuts show concern about costs and valuation realism. Overall pros: strong pipeline optionality, multiple Buy ratings, and meaningful upside targets. Cons: skepticism about pipeline quality versus peers, rising expenses, and heavy dependence on clinical success.
